FinanceCity
HealthcareNSE · BSE

Aarti Drugs Limited

AARTIDRUGS · ISIN INE767A01016

Share price

₹372 -0.85%

Market capitalisation

₹3397 CrClosed

Live from Yahoo Finance. Pulse animates during NSE market hours (9:15–15:30 IST, weekdays).

01 · Key metrics

Market cap

₹3397 Cr

Current price

₹372

-0.85% today

52W high

₹564

52W low

₹319

Stock P/E

17.43

P/B ratio

2.19

02 · Per share & returns

EPS (TTM)

₹21.36

Book value

₹170

ROE

13.36%

ROA

5.67%

Dividend yield

0.53%

Beta

0.36

03 · Financials (TTM)

By the numbers

Revenue

₹2565 Cr

+6.40% YoY

EBITDA

₹312 Cr

Net profit

₹195 Cr

-12.00% YoY

Profit margin

7.60%

Operating margin

10.90%

Total debt

₹577 Cr

Total cash

₹24.28 Cr

Debt / equity

0.37x

Current ratio

1.59x

Payout ratio

9.36%

04 · Analyst view

Target price

₹439

Upside

+17.95%

Consensus

NONE

Analysts

1

05 · Shareholding pattern

Who owns AARTIDRUGS?

Shareholding pattern not yet captured for this company. Pulled from NSE corporate filings on the next ownership refresh.

06 · Registration & listing

On the record

Symbol
AARTIDRUGS
Exchange
NSE · BSE
CIN
ISIN
INE767A01016
BSE code
524348
Sector
Healthcare
Industry
Healthcare
Face value
₹10
Listing date
18 Sept 2003
Employees
Headquarters
Mumbai, India

07 · About

What is Aarti Drugs Limited?

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.

08 · Common questions

Frequently asked

What is the CIN of Aarti Drugs Limited?+

The Corporate Identity Number for Aarti Drugs Limited is published in the MCA21 corporate master. FinanceCity backfills CIN values during weekly refreshes.

Who are the promoters of Aarti Drugs Limited?+

Promoter and group-holding details for Aarti Drugs Limited are disclosed quarterly via stock-exchange filings. Detailed pattern is refreshed weekly here from BSE and NSE corporate filings.

What is the market capitalisation of Aarti Drugs Limited?+

Aarti Drugs Limited (AARTIDRUGS) has a market capitalisation of approximately ₹3397 Cr, reflecting the most recent weekly refresh from the BSE scrip master.

09 · Adjacent

Other healthcare listings

Full sector →